SCHEMBL4124192

SCHEMBL4124192

CN(C)c1ccc(-c2ccc(CC=C3SC(Nc4ccc(CC(=O)NS(=O)(=O)c5ccc(C(F)(F)F)cc5)cc4)=NC3=O)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 5/20 0.38
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
EGFR P00533 8/20 0.36
ERBB2 P04626 8/20 0.36
PPARG P37231 1/20 0.35
RAB9A P51151 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NR2E3 Q9Y5X4 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
ALDH1A1 P00352 1/20 0.34
BCL2L1 Q07817 1/20 0.34
MCL1 Q07820 1/20 0.34
PPARA Q07869 1/20 0.34
CCR3 P51677 1/20 0.34
FLT1 P17948 1/20 0.33
FLT4 P35916 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636269 0.91 BCL2 (0.39) RORCCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4635196 0.91 BCL2 (0.39) RORCCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4634500 0.82 EGFR (0.45) RORCEGFRERBB2BCL2L1MCL1
SCHEMBL4123481 0.81 BCL2 (0.45) RORCEGFRERBB2ALDH1A1BCL2L1
SCHEMBL4123479 0.81 BCL2 (0.45) RORCEGFRERBB2ALDH1A1BCL2L1
SCHEMBL4133309 0.76 RORC (0.36) RORCEGFRERBB2ALDH1A1BCL2L1
SCHEMBL4133312 0.76 RORC (0.36) RORCEGFRERBB2ALDH1A1BCL2L1
SCHEMBL4128290 0.76 PTGS1 (0.42) RORCEGFRERBB2
SCHEMBL4128292 0.76 PTGS1 (0.42) RORCEGFRERBB2
SCHEMBL4125880 0.76 ACKR3 (0.39) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ RORC 274/4885CYP3A4 1124/4885CYP2D6 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.